keyword
MENU ▼
Read by QxMD icon Read
search

503a OR 503b

keyword
https://www.readbyqxmd.com/read/30100684/fda-guidance-on-503b-provides-leeway-outsourcing-facilities-can-be-co-located-with-503a-pharmacies
#1
Stephen Barlas
FDA guidance on outsourcing facilities and 503A pharmacies.
August 2018: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/29877860/quality-control-lessons-learned-from-a-trimix-stability-study-in-a-503a-compounding-pharmacy
#2
Rick Rhoads
Changes in California regulations regarding beyond-use dates of sterile preparations have prompted many compounders to consider stability studies for their formulas. Traditionally, 503A compounders have relied on published data and professional experience to determine stability. However, due to these new regulations, stability studies are now required for California resident and nonresident licensees to extend the beyond-use date of sterile preparations. Conducting studies for the first time can be costly and difficult for compounding pharmacists...
March 2018: International Journal of Pharmaceutical Compounding
https://www.readbyqxmd.com/read/29877857/pharmacogenomics-precision-pharmacy-in-503a-compounding
#3
Joseph Drummond, Daron Bennet, Loyd V Allen
The first recorded mention of a pharmacogenomic response may be that of Pythagoras in 510 BC, when he noted that hemolytic anemia developed in some but not all people who ingested fava beans. The application of such accounts to pharmacotherapy was inevitable, and customized medications have been compounded since antiquity to treat the needs of individual patients. Today, advances in pharmacogenomic testing yield results that enable more effective targeted therapies sooner in the course of treatment, prevent drug-related adverse effects, save cost, and ensure a better therapeutic outcome...
March 2018: International Journal of Pharmaceutical Compounding
https://www.readbyqxmd.com/read/29385381/certification-accreditation-and-credentialing-for-503a-compounding-pharmacies
#4
Jon Pritchett, Gary McCrory, Cheri Kraemer, Brenda Jensen, Loyd V Allen
The terms certification, accreditation, and credentialing are often used interchangeably when they apply to compounding-pharmacy qualifications, but they are not synonymous. The reasons for obtaining each, the requirements for each, and the benefits of each differ. Achieving such distinctions can negatively or positively affect the status of a pharmacy among peers and prescribers as well as a pharmacy's relationships with third-party payors. Changes in the third-party payor industry evolve constantly and, we suggest, will continue to do so...
January 2018: International Journal of Pharmaceutical Compounding
https://www.readbyqxmd.com/read/29216613/documentation-records-and-reports
#5
Michael J Akers
This article deals with documentation to include the beginning of documentation, the requirements of Good Manufacturing Practice reports and records, and the steps that can be taken to minimize Good Manufacturing Practice documentation problems. It is important to remember that documentation for 503a compounding involves the Formulation Record, Compounding Record, Standard Operating Procedures, Safety Data Sheets, etc. For 503b outsourcing facilities, compliance with Current Good Manufacturing Practices is required, so this article is applicable to them...
September 2017: International Journal of Pharmaceutical Compounding
https://www.readbyqxmd.com/read/28557780/microbiologic-testing-for-503a-sterile-compounding-pharmacies
#6
William Mixon, Abby Roth
Compounding pharmacists must ensure that the sterile preparations they dispense are free of microbiologic contamination. Working in a cleanroom under controlled conditions (proper differential air pressure, temperature, and humidity; acceptable levels of viable and nonviable airborne particles and surface counts, etc.) and testing the efficacy of cleaning and disinfecting practices via environmental monitoring (viable-air and surface testing, glove-fingertip-thumb testing, etc.) are essential to preparing contamination-free medications...
May 2017: International Journal of Pharmaceutical Compounding
https://www.readbyqxmd.com/read/28357118/a-phase-1-study-comparing-the-proposed-biosimilar-bs-503a-with-bevacizumab-in-healthy-male-volunteers
#7
Naoyuki Tajima, Alberto Martinez, Fumiaki Kobayashi, Ling He, Peter Dewland
This is a randomized, double-blind, single-dose, parallel group phase 1 study to assess pharmacokinetic similarity, safety, and tolerability of BS-503a, a proposed bevacizumab biosimilar. A total of 114 male healthy subjects were randomized (1:1) to receive a single 3 mg/kg intravenous dose of either BS-503a or bevacizumab (Avastin(®)). Pharmacokinetic (PK) blood samples were collected up to Day 78, and serum drug concentrations were measured using a validated enzyme-linked immunosorbent assay. Pharmacokinetic similarity was evaluated using area under the serum concentration-time curve from zero to infinity (AUC inf) as a primary PK parameter, and maximum serum concentration (Cmax) and area under the serum concentration-time curve from zero to the last measurable time (AUC last) as secondary PK parameters...
April 2017: Pharmacology Research & Perspectives
https://www.readbyqxmd.com/read/28346203/u-s-food-and-drug-administration-inspections-guide-to-a-successful-outcome-for-503a-sterile-compounding-pharmacies
#8
Doug Yoch
The reasons for which pharmaceutical compounding is the focus of intense state and federal scrutiny are now well known. Compounders are faced with an ever-increasing need to prove, by objective standards, the safety, purity, and potency of the formulations they dispense. They must also demonstrate their compliance with regulations often based on current good compounding practices designed for the pharmaceutical industry. In the U.S. today, rigorous unannounced state and federal inspections of compounding facilities are occurring more and more frequently...
March 2017: International Journal of Pharmaceutical Compounding
https://www.readbyqxmd.com/read/28333673/choosing-a-vial-processing-line-for-aseptic-compounding-part-1
#9
REVIEW
Shaun Noorian, Navid Vahedi
Equipment systems that enable compliance with stringent state and federal compounding requirements are a topic of increasing interest to U.S. pharmacists. Of those equipment types, an aseptic vial processing line offers unique benefits (especially to 503B compounding pharmacies and small contract manufacturers of aseptic pilot-size batches) if the volume of sterile preparations dispensed offsets the cost of purchase, installation, and maintenance. In this article, the reasons for and the process of selecting an aseptic vial processing line for use in 2 independent 503B compounding pharmacies are presented, the operation of our choice of equipment is described, and specifications for the components of that line are listed...
July 2016: International Journal of Pharmaceutical Compounding
https://www.readbyqxmd.com/read/27882080/a-novel-krt5-mutation-associated-with-generalized-severe-epidermolysis-bullosa-simplex-in-a-2-year-old-chinese-boy
#10
Jia Zhang, Ming Yan, Jianying Liang, Ming Li, Zhirong Yao
Mutations in keratin 5 (KRT5) or KRT14 genes are responsible for the most severe form of epidermolysis bullosa simplex (EBS), which is EBS generalized severe (EBS-gen sev). To date, only four pathogenic mutations (p.Arg165Ser and p.Lys199Asn in KRT5; p.Arg125Cys and p.Arg125His in KRT14) have been reported to be responsible for EBS-gen sev in the Chinese population. In the present study, a 2-year-old Chinese boy was clinically suspected to suffer from EBS, and thus Sanger sequencing was performed in the extracted genomic DNA samples from the patient, his parents and 100 healthy controls...
November 2016: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/27731962/additions-and-modifications-to-the-list-of-drug-products-that-have-been-withdrawn-or-removed-from-the-market-for-reasons-of-safety-or-effectiveness-final-rule
#11
(no author information available yet)
The Food and Drug Administration (FDA or the Agency) is amending its regulations to revise the list of drug products that have been withdrawn or removed from the market because the drug products or components of such drug products have been found to be unsafe or not effective. Drugs appearing on this list may not be compounded under the exemptions provided by sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (the FD&C Act). Specifically, the rule adds 24 entries to this list of drug products, modifies the description of one entry on this list, and revises the list's title and introductory language...
October 7, 2016: Federal Register
https://www.readbyqxmd.com/read/27125054/performance-improvement-in-503a-compounding-pharmacies-a-plan-for-assessment-implementation-and-sustained-success
#12
Jon Pritchett, William Mixon, Kevin O'Connell
Performance improvement is the continual effort to objectively assess current performance and then restructure the practices that support it to more closely achieve desired performance. A plan for performance improvement, unlike other approaches to correcting problems in job fulfillment, is a systematic method used to first find the root causes of areas of concern and then apply corrections to remedy those deficits. Implementing a performance improvement plan that can be easily adapted to ensure compliance with evolving and increasingly complex state and federal regulations is crucial to a successful compounding practice...
January 2016: International Journal of Pharmaceutical Compounding
https://www.readbyqxmd.com/read/26775444/the-evolution-of-21-cfr-parts-210-211-for-drug-compounders-an-unspoken-opportunity-for-pharmacists
#13
Kenneth Chase Parks, Brian Bernard, Christopher Blake Cogdill
A high-level assessment of recent U.S. Food and Drug Administration audits of 503A facilities indicates that a regulatory paradigm shift is occurring. Data and rationale further indicates that the agency seems to be taking a proactive approach for how it monitors these facilities. The auditing practices and observations are eerily similar to those which are seen for 503B Outsourcing Facilities, as well as Current Good Manufacturing Practices Drug and Device Manufacture plants. Perhaps the U.S. Food and Drug Administration is attempting to avoid any major medical outbreaks that may stem from under-supervised drug preparation centers...
September 2015: International Journal of Pharmaceutical Compounding
https://www.readbyqxmd.com/read/26418479/update-on-medical-and-regulatory-issues-pertaining-to-compounded-and-fda-approved-drugs-including-hormone-therapy
#14
REVIEW
JoAnn V Pinkerton, James H Pickar
OBJECTIVE: We review the historical regulation of drug compounding, concerns about widespread use of non-Food and Drug Admiistration (FDA)-approved compounded bioidentical hormone therapies (CBHTs), which do not have proper labeling and warnings, and anticipated impact of the 2013 Drug Quality and Security Act (DQSA) on compounding. METHODS: US government websites were searched for documents concerning drug compounding regulation and oversight from 1938 (passage of Federal Food, Drug, and Cosmetic Act [FDCA]) through 2014, including chronologies, Congressional testimony, FDA guidelines and enforcements, and reports...
February 2016: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/26417174/two-draft-fda-guidance-documents-stir-controversy-hospital-and-503b-pharmacy-repackaging-and-compounding-are-at-issue
#15
Stephen Barlas
The Food and Drug Administration hopes to close gaps in laws related to repackaging of pharmaceuticals or biologics by hospital pharmacies and bulk compounding facilities.
September 2015: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/25906620/depyrogenation-options-for-the-compounding-cleanroom
#16
Tom Weller, Jeff Bell, Roger Dullinger, Vern Allen, Bruce Anthenat
Compounding pharmacies, especially those awarded 503B status under the U.S. Federal Food, Drug, and Cosmetic Act that resulted from the Drug Quality and Security Act, must meet increasingly strict standards for the preparation of sterile formulations. Depyrogenating the containers and tools used in such compounding is essential to meeting those standards and ensuring patient safety. Although pyrogens are relatively thermally stable, treating aseptic-compounding glassware and implements in a dry-heat oven or tunnel is the most common method of depyrogenation...
November 2014: International Journal of Pharmaceutical Compounding
https://www.readbyqxmd.com/read/25577886/final-guidance-for-pharmacy-compounding-of-human-drug-products-under-section-503a
#17
Cynthia E Blankenship
No abstract text is available yet for this article.
September 2014: International Journal of Pharmaceutical Compounding
https://www.readbyqxmd.com/read/25395814/fda-s-proposed-503b-draft-compounding-guidance-raises-concerns-of-all-kinds-is-the-bar-being-set-too-high-or-too-low
#18
Stephen Barlas
FDA draft guidance on 503B compounding widely faulted.
November 2014: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/25050055/fda-draft-guidances-compound-the-compounding-uncertainty-a-new-list-of-503b-outsourcing-facilities-offers-no-guarantee-of-anything
#19
Stephen Barlas
Compounders who prepare nonpatient-specific prescriptions have been slow to sign up for a new FDA program meant to serve as a de facto "Good Housekeeping" seal of approval. Meanwhile, inspectors are turning up problems wherever they go.
June 2014: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/23829193/retrospective-study-of-the-medium-chain-acyl-coa-dehydrogenase-deficiency-in-portugal
#20
F V Ventura, P Leandro, A Luz, I A Rivera, M F B Silva, R Ramos, H Rocha, A Lopes, H Fonseca, A Gaspar, L Diogo, E Martins, E Leão-Teles, L Vilarinho, I Tavares de Almeida
Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) is the commonest genetic defect of mitochondrial fatty acid β-oxidation. About 60% of MCADD patients are homozygous for the c.985A>G (p.Lys329Glu) mutation in the ACADM gene (G985 allele). Herein, we present the first report on the molecular and biochemical spectrum of Portuguese MCADD population. From the 109 patients studied, 83 were diagnosed after inclusion of MCADD in the national newborn screening, 8 following the onset of symptoms and 18 through segregation studies...
June 2014: Clinical Genetics
keyword
keyword
165562
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"